Mural Oncology Achieves Required Overall Survival Events in Trial, Extends Cash Runway

MT Newswires Live
01-10

Mural Oncology (MURA) said Thursday it achieved 75% of the required overall survival events for the planned interim analysis in its ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab for platinum-resistant ovarian cancer.

The company said it extended its cash runway projection into Q1 2026.

Mural also expanded its pipeline in Q4 2024 by nominating two new development candidates for its interleukin-18 and interleukin-12 programs, it added.

The company said it anticipates filing an Investigational New Drug application or Clinical Trial Application for a phase 1 trial of MURA-8518 in Q4 2025.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10